Podcasts about cardiology acc

Video Version Only on HCPLive! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explored two key trial updates in type 2 diabetes (T2D) care at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions. SOUL Trial SOUL, a double-blind, placebo-controlled, event-driven trial, was designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). A total of 9650 patients aged ≥50 years were enrolled across 450 centers in 44 countries. Analyses showed oral semaglutide (Rybelsus) was linked to a 14% reduction in major adverse cardiovascular events (MACE) in high-risk patients with T2D. This reduction included the incidence of cardiovascular (CV) death, myocardial infarction (MI), or stroke compared to placebo (HR, 0.86; 95% CI, 0.77 to 0.96; P = .006) over a median follow-up of 47.5 months. A 26% reduction in non-fatal MI was the primary driver of benefit, while safety findings identified gastrointestinal adverse events as more common with oral semaglutide. Based on these results, Novo Nordisk announced plans to pursue regulatory approval for a label expansion of oral semaglutide to include MACE risk reduction in adults with T2D and established CV disease. STRIDE Trial STRIDE, a double-blind, randomized, placebo-controlled trial initiated in 2020, assessed the effects of semaglutide 1.0 mg (Ozempic) on functional outcomes, including walking distance, in patients with T2D and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial randomized 792 patients to receive semaglutide or placebo for 52 weeks. Analyses showed semaglutide use was associated with improvements in maximal walking distance, quality of life, and ankle-brachial index (ABI). SOUL met its primary endpoint, with semaglutide favoring the ratio from baseline in maximum walking distance at 52 weeks (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). At week 57, the improvement in walking distance was higher with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011), as were improvements in pain-free walking distance (ETR, 1.11; P = .0046). Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. Editor's Note: In this episode, there was an error in the discussion about the new dosing for Rybelsus in the SOUL trial. The corrected information is that the 14 mg dose is now 9 mg with the new formulation, due to improved absorption. The full corrected statement is: “Instead of 3 mg, the new dose is 1.5 mg; instead of 7 mg, it's 4 mg; and instead of 14 mg, it's 9 mg.”

Send us a textEpisode 112 - Top Papers from the 2025 American College of Cardiology (ACC) SessionWelcome back Rounds Table Listeners! We are back today with a special Rapid Fire Podcast! This week, Drs. Mike and John Fralick discuss top papers from the 2025 American College of Cardiology (ACC) Annual Scientific Session. Hot off the presses, here we go!Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (0:00 - 5:55)Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation (DapaTAVI) (5:56 - 9:51)Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (9:52 - 14:04)Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE) (14:05 - 18:36)The Good Stuff:The Studio TV series on Apple (18:37 - 19:11)Cardiology Trial Files (19:12 - 20:40)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePodsSupport the show

Send us a textWelcome back Rounds Table Listeners! We are back today with a special Rapid Fire Podcast! This week, Drs. Mike and John Fralick discuss top papers from the 2025  American College of Cardiology (ACC) Annual Scientific Session. Hot off the presses, here we go!Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (0:00 - 5:55)Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation (DapaTAVI) (5:56 - 9:51)Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (9:52 - 14:04)Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE) (14:05 - 18:36)The Good Stuff:The Studio TV series on Apple (18:37 - 19:11)Cardiology Trial Files (19:12 - 20:40)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

This episode of Don't Miss a Beat, recorded at the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, explores the evolving landscape of heart failure with preserved ejection fraction (HFpEF) treatment, focusing on the implementation of combination therapies. Hosts Steve Greene, MD, and Muthiah Vaduganathan, MD, MPH, discuss the transition from a previously limited treatment landscape to a new era with multiple proven therapeutic options. To open the episode, Greene argues in favor of rapid-sequence implementation of HFpEF therapies, drawing parallels to the established 4-pillar guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF). He highlights 3 key classes of medications—SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and incretin-based therapies—as the foundation of HFpEF treatment. He emphasizes the importance of early and aggressive therapy initiation to maximize clinical benefits and reduce the risk of delayed or missed treatment opportunities among this population. Vaduganathan acknowledges the strength of the data supporting combination therapy but suggests a more risk-based approach, considering the broad clinical variability among HFpEF patients. He advocates for prioritizing rapid implementation in high-risk patients, such as those recently hospitalized, while allowing a more measured approach for lower-risk individuals. The discussion also touches on the role of phenotyping in tailoring treatment decisions, with GLP-1 receptor agonists being particularly relevant for patients with obesity and ARNi potentially benefiting those with mildly reduced ejection fraction. Looking ahead, the hosts preview upcoming trials, including CONFIDENCE and CONFIRMATION, which will evaluate combination therapy strategies in chronic kidney disease and HFpEF populations. They also discuss the potential of fixed-dose combination therapies to simplify implementation and improve adherence. The episode closes with both experts agreeing on the need for a structured, evidence-based approach to HFpEF treatment while emphasizing the importance of translating trial data into real-world practice. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00-Intro 02:30-Argument for Rapid Sequencing 05:32-Argument Against Rapid Sequencing 10:00-Argument for Risk-Based Sequencing 14:25-Pillars of GDMT in HFpEF

In this on-site episode of Don't Miss a Beat from the American College of Cardiology (ACC) 2025 Annual Scientific Sessions, hosts Muthiah Vaduganathan, MD, MPH, and Steve Greene, MD, break down a pair of trials from the meeting: STRIDE and SOUL. STRIDE Trial The STRIDE trial, funded by Novo Nordisk, was a double-blind, randomized, placebo-controlled study initiated in 2020 to evaluate the effects of semaglutide 1.0 mg (Ozempic) on walking distance in patients with type 2 diabetes (T2D) and peripheral artery disease (PAD). Conducted across 112 sites in 20 countries, the trial enrolled 792 patients, who were randomized 1:1 to receive semaglutide or placebo for 52 weeks. Participants assigned to semaglutide received an escalating dose regimen (0.25 mg to 1.0 mg). The primary endpoint, the ratio from baseline in maximum walking distance at 52 weeks, favored semaglutide (1.21 [interquartile range, 0.95–1.55] vs 1.08 [0.86–1.36]), with an estimated treatment ratio (ETR) of 1.13 (95% CI, 1.06–1.21; P = .0004). Secondary outcomes further supported semaglutide's benefit. At week 57, the improvement in walking distance was greater with semaglutide (ETR, 1.08; P = .038). Quality-of-life scores (VascuQoL-6) at week 52 were significantly higher in the semaglutide group (median difference, 1.00; P = .011). Pain-free walking distance also improved more with semaglutide than with placebo (ETR, 1.11; P = .0046). SOUL Trial The SOUL trial was a double-blind, placebo-controlled, event-driven study designed to assess the cardiovascular effects of oral semaglutide (Rybelsus) in patients with T2D and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). The trial enrolled 9650 patients aged ≥50 years and was conducted across 450 centers in 44 countries. Participants were randomized 1:1 to receive semaglutide or placebo, with a mean follow-up of 47.5 months. Primary outcome events occurred in 12.0% of participants receiving semaglutide (3.1 events per 100 person-years) compared with 13.8% in the placebo group (3.7 events per 100 person-years), resulting in a hazard ratio (HR) of 0.86 (95% CI, 0.77–0.96; P = .006). The primary driver of benefit was a 26% reduction in nonfatal myocardial infarction, with additional reductions in nonfatal stroke (12%) and cardiovascular death (7%). No significant improvements in kidney function were observed. Serious adverse events occurred slightly less frequently in the semaglutide group compared with placebo (47.9% vs 50.3%; P = .02). However, gastrointestinal adverse events, including nausea, diarrhea, constipation, and flatulence, were more common in the semaglutide group (5.0% vs 4.4%). Benefits were consistent across subgroups, including participants receiving sodium-glucose cotransporter-2 inhibitors. Relevant disclosures for Vaduganathan include Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, Lexicon, and others. Relevant disclosures for Greene include Amgen, AstraZeneca, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Cytokinetics, and others. Chapters 00:00 - Intro 00:50 - STRIDE Background 02:50 - STRIDE Results 08:19 - SOUL Background 10:40 - SOUL Results

In April 2024, Cathie Biga, MSN, FACC, made history as the first non-physician president of the American College of Cardiology (ACC). On this episode of HeartTalk, Melanie Lawson, MS, talks with Cathie about her 40+ years of experience as a leader in cardiovascular care. She shares personal, inspiring and educational stories about her career and discusses her vision for the future.Watch the HeartTalk with Cathie ACC President Series here:https://www.acc.org/accpresidentCathleen Biga, MSN, FACCACC PresidentCathleen Biga, MSN, FACC, is President and CEO of Cardiovascular Management of Illinois, a cardiology physician practice management company. She has worked with more than 100 cardiovascular providers in the Chicago area and partners in their cardiovascular service lines at more than 14 acute care hospitals. She earned her Bachelor of Science degree in nursing from the Mayo/College of St. Teresa and Master of Science in Nursing from Northern Illinois University School of Nursing. Biga has more than 40 years of experience as a registered nurse, service line director, hospital vice president and CEO. She has 30 years of experience in physician practice management.She has been active nationally in consulting, strategic planning, operational efficiencies, integrated financial and quality initiatives, and growth and development of the cardiovascular service lines. She is focused on facilitating the integration of strategic, financial and quality perspectives between cardiovascular service lines at practices and hospitals. In addition, she consults and lectures on numerous contemporary cardiovascular topics.Biga is a member of ACC's Board of Trustees, a past member of the American Association of Cardiovascular and Pulmonary Rehabilitation Board and was the Inaugural Chair of MedAxiom's Board of Managers.

Tachycardia in pregnancy is common and distinguishing between physiological and pathological causes can be a challenge. Plus, until recently, there had not been a well-defined or universally accepted definition of the upper limit of normal for heart rate in pregnancy. But a study published in 2020 from the Green Journal, from the NHS in London has shed light on this issue. The finding of persistent tachycardia beyond a certain rate (and we'll discuss that rate in this episode), regardless of symptoms, should prompt a search for potential etiologies and at least some basic investigations. Of course, any tachyarrhythmia in pregnancy causing hemodynamic instability requires urgent cardioversion as per adult life support guidelines. In 2023, The Heart Rhythm Society (HRS) developed expert consensus guidelines in collaboration with the American College of Cardiology (ACC), the ACOG, and the AHA to address arrhythmias in pregnancy. In this episode we will focus on and review maternal tachycardia. Does HR really increase by “10-20%” in pregnancy as we all were taught? What heart rate is generally considered evaluable? And what's the suggested evaluation? Listen in for details.

On this episode of MedAxiom HeartTalk, host Melanie Lawson, MS, explores the transformative potential of artificial intelligence (AI) for cardiovascular care with guests Effie Andrikopoulou, MD, MBA, FACC, FASE, associate professor at the University of Washington and medical director at Harborview Medical Center, and Denise Busman, MSN, RN, CPHQ, FACC, vice president of Care Transformation Services at MedAxiom. They explore how care teams can integrate AI into everyday practice and consider the current challenges and opportunities to improve patient outcomes. Guest Bios:Effie Andrikopoulou, MD, MBA, FACC, FASE Dr. Andrikopoulou is an associate professor of Medicine at the University of Washington and the medical director of the Echocardiography Lab at Harborview Medical Center. She completed her internal medicine training at Thomas Jefferson University in Philadelphia, cardiology fellowship at the University of Alabama at Birmingham (UAB), and advanced multimodality cardiovascular imaging training at Brigham and Women's Hospital in Boston. Dr. Andrikopoulou also holds an MBA from UAB. She is an expert in cardiovascular imaging, and her clinical niche is cardio-oncology. Dr. Andrikopoulou is a rising leader in the space of artificial intelligence (AI). She is passionate about developing and implementing AI ("collaborative intelligence") algorithms to optimize clinical workflows and ensure delivery of high-quality, equitable care to all patients and communities irrespective their socioeconomic and cultural backgrounds. Her expertise has been recognized with several awards, including the 2016 Rising Stars in Healthcare in Alabama and the 2016 American Heart Association Women in Cardiology Trainee Award for Excellence.Denise Busman, MSN, RN, CPHQ, FACC As Vice President of Care Transformation Services at MedAxiom, Denise brings more than 30 years of experience as a cardiovascular clinician and leader to her role. Her clinical expertise is complemented by a passion for engaging multidisciplinary teams to transform care delivery and enhance clinical quality. Known for her work in program development and change management, Denise is skilled in the implementation of new programs and clinical initiatives. Denise joined MedAxiom from Corewell Health, formerly known as Spectrum Health – a multi-hospital system in Michigan, where she held a variety of positions including critical care educator and cardiology clinical nurse specialist. Most recently, her focus was directed toward clinical improvement and quality for the cardiovascular service line, where she implemented innovative approaches to care and served as a trusted advisor to cardiovascular physicians and team members. Denise holds a bachelor's degree in nursing from Michigan State University and master's degree in nursing from Grand Valley State University. She has been active with the American College of Cardiology (ACC) for many years as a Michigan Chapter board member, cardiovascular team liaison, ACC Scientific Program Committee member and reviewer of scientific abstracts.

In this episode the incredible Dr Thomas Levy, Board Certified Cardiologist and Attorney, author of 13 books including: Curing the Incurable - the Vitamin C story and it's therapeutic effects The Hidden Epidemic - the story around dental infections, root canals and their affect on cardiovascular disease and breast cancer and beyond. Death by Calcium - the truth about calcium and why supplementing with calcium is a bad idea. Rapid Virus Recovery - all about dealing with viruses successfully  Magnesium: Reversing Disease  Dr Thomas has been on this show twice so make sure you also listen in to those episodes  Curing the Incurable all about IV and oral Vitamin C  (this one has had over 150,000 views/listens.    and Rapid Virus Recovery   In this episode we dive into Dr Thomas's latest learnings and his top 8 (affordable) supplements and why he thinks most people would benefit from these and how they work in the body.   We dive into his research on Methylene Blue and its ability to help those with mitochondrial dysfunction and energy problems.    We also get into why 100% of root canals are infected and the terrible effect that can have on your risks for developing heart disease and also breast cancer.    We dive again into the benefits and many faceted roles that vitamin C plays in the body as not only a powerful antioxidant but how it has the ability to get everywhere in the body and why that makes it much more powerful than many other antioxidants and we discuss it's roles in everything from cancer to covid to sepsis to cardiovascular disease and osteoporosis.   We also discuss his indepth research into why calcium is so detrimental when it is higher in the body than it should be and why just a small increase of calcium in the soft tissues outside of bone and teeth has such deleterious effects and why magnesium is so beneficial and how it counteracts calciums deleterious effects in the body.   We also look into iron and how it promotes cancer and why it can be elevated in people suffering with viruses and pathogens that are chronic. We also discuss copper toxicity and why so many have too much free copper which can be as toxic as mercury.   Antimony is another topic we get into and why it's so high in the population.   Lastly we dive into osteoporosis why it's actually focal scurvy and a lack of vitamin C.   This episode is a masterclass in health optimisation that you will want to repeat over and over again.   To subscribe to Dr Levy's newsletter and to read his articles, get copies of his books etc go to  https://www.tomlevymd.com/   You can also read many of his in depth articles on the Orthomolecular New Service at  https://www.tomlevymd.com/     BIO   Johns Hopkins University, 1968-72—B.A., Biology Tulane University School of Medicine, 1972-76—M.D. University of Denver College of Law, 1995-98—J.D. Post-Graduate Training: Internship and Internal Medicine Residency, 1976-79, Tulane University Affiliated Hospitals Fellowship in Cardiology, 1979-81, Tulane University Affiliated Hospitals LICENSURE AND CERTIFICATION: Federal Licensing Examination (FLEX), 1976 American Board of Internal Medicine, Internal Medicine Board Certification, 1979 Cardiovascular Diseases Subspecialty Board Certification, 1981 Admitted to Colorado Bar, 1998 Admitted to District of Columbia Bar, 1999 PROFESSIONAL ORGANIZATIONS: Advanced Amateur Radio Operator, 1974—present [WB5CTC] American College of Physicians (ACP), Member, 1980—2002 Louisiana State Medical Society, 1976-91 American College of Cardiology (ACC), Fellow, 1983—present American Society of Clinical Hypnosis (ASCH), Member, 1990-2000 El Paso County Medical Society (Colorado), 1991-1995 American Inn of Court, Judge William E. Doyle Inn, Pupil, 1997-8; Associate Barrister, 1999 to present Colorado Bar Association, 1998-2002 El Paso County Bar Association, 1999 American College of Forensic Examiners (ABFM), Member, 1999 American College of Forensic Examiners (ABFM), Diplomate, 1999 Induction into the Orthomolecular Medicine Hall of Fame, April 2016 PROFESSIONAL POSITIONS AND HOSPITAL AFFILIATIONS: Supervisor, Major Medical Emergency, Charity Hospital of New Orleans, 1980-83 Assistant Professor of Medicine, Tulane Medical School, 1981-83 Clinical Investigator, DDD Pacemaker, entitled "Clinical Study for Telectronics Model 2251, Dual Chamber Pulse Generator" Member, Formulary Review—Cardiovascular Section, Charity Hospital of New Orleans, 1981-83 Instructor in Radiology, Tulane Medical School, 1983-4 Clinical Assistant Professor of Medicine, Tulane Medical School, 1983-1986 Staff, Iberia General Hospital, New Iberia, Louisiana, 1984-91 Staff, Memorial Hospital, Colorado Springs, Colorado, 1991-present Staff, Denver General Hospital, Denver, Colorado, 1995-6 Medical Technical Advisor, International Tesla Society, Colorado Springs, Colorado, 1994-8 PUBLICATIONS Graybar, G., Goethe, J., Levy, T., Phillips, J., Youngberg, J., and Smith, D., "Transient Large Upright T-Wave During Multiple Monitored Electroconvulsive Therapy," Anesthesiology, 59(5):467-469 (1983). Levy, T., Trauma Rounds "Problem: Cardiac Contusion," Annals of Emergency Medicine, July 15, 1983. Levy, T. and Huggins, H., "Routine Dental Extractions Routinely Produce Cavitations," Journal of Advancement in Medicine, 9(4):235-249 (1996) Huggins, H. and Levy, T., "Cerebrospinal Fluid Protein Changes in Multiple Sclerosis After Dental Amalgam Removal," Alternative Medicine Review, 3(4):295-300 (1998) Huggins, H. and Levy, T., Uninformed Consent: The Hidden Dangers in Dental Care, Charlottesville, VA: Hampton Roads Publishing Company, Inc.; 1999 Levy, T., Optimal Nutrition for Optimal Health: The Real Truth About Eating Right for Weight Loss, Detoxification, Low Cholesterol, Better Digestion, and Overall Well-Being, New York, NY: McGraw-Hill (Keats Publishing); 2001 Kulacz, R. and Levy, T., The Roots of Disease: Connecting Dentistry and Medicine, Philadelphia, PA: Xlibris Corporation; 2002 Levy, T., Curing the Incurable: Vitamin C, Infectious Diseases, and Toxins, Henderson, NV: Medfox Publishing; 2002 Levy, T., Stop America's #1 Killer! Reversible Vitamin Deficiency Found to be Original of ALL Coronary Heart Disease, Henderson, NV: Medfox Publishing; 2006 Levy, T., GSH: Master Defender Against Disease, Toxins, and Aging, Henderson, NV: Medfox Publishing; 2008 Levy, T., Living in Your Right Mind, Henderson, NV: Medfox Publishing; 2010 Levy, T., Primal Panacea, Henderson, NV: MedFox Publishing; 2011 Levy, T., Death by Calcium, Henderson, NV: MedFox Publishing; 2013 Kulacz, R. and Levy, T., The Toxic Tooth, Henderson, NV: MedFox Publishing; 2014 Levy, T., Hidden Epidemic, Henderson, NV: MedFox Publishing; 2017 Levy, T., Magnesium: Reversing Disease, Henderson, NV: MedFox Publishing; 2019 Levy, T., Rapid Virus Recovery: No need to live in fear!, Henderson, NV: MedFox Publishing; 2021   Personalised Health Optimisation Consulting with Lisa Tamati Lisa offers solution focused coaching sessions to help you find the right answers to your challenges. Topics Lisa can help with:  Lisa is a Genetics Practitioner, Health Optimisation Coach, High Performance and Mindset Coach. She is a qualified Ph360 Epigenetics coach and a clinician with The DNA Company and has done years of research into brain rehabilitation, neurodegenerative diseases and biohacking. She has extensive knowledge on such therapies as hyperbaric oxygen,  intravenous vitamin C, sports performance, functional genomics, Thyroid, Hormones, Cancer and much more. She can assist with all functional medicine testing. Testing Options Comprehensive Thyroid testing DUTCH Hormone testing Adrenal Testing Organic Acid Testing Microbiome Testing Cell Blueprint Testing Epigenetics Testing DNA testing Basic Blood Test analysis Heavy Metals  Nutristat Omega 3 to 6 status and more  Lisa and her functional medicine colleagues in the practice can help you navigate the confusing world of health and medicine . She can also advise on the latest research and where to get help if mainstream medicine hasn't got the answers you are searching for whatever the  challenge you are facing from cancer to gut issues, from depression and anxiety, weight loss issues, from head injuries to burn out to hormone optimisation to the latest in longevity science. Book your consultation with Lisa    Join our Patron program and support the show Pushing the Limits' has been free to air for over 8 years. Providing leading edge information to anyone who needs it. But we need help on our mission.  Please join our patron community and get exclusive member benefits (more to roll out later this year) and support this educational platform for the price of a coffee or two You can join by going to  Lisa's Patron Community Or if you just want to support Lisa with a "coffee" go to  https://www.buymeacoffee.com/LisaT to donate $3   Lisa's Anti-Aging and Longevity Supplements  Lisa has spent years curating a very specialized range of exclusive longevity, health optimizing supplements from leading scientists, researchers and companies all around the world.  This is an unprecedented collection. The stuff Lisa wanted for her family but couldn't get in NZ that's what it's in her range. Lisa is constantly researching and interviewing the top scientists and researchers in the world to get you the best cutting edge supplements to optimize your life.   Subscribe to our popular Youtube channel  with over 600 videos, millions of views, a number of full length documentaries, and much more. You don't want to miss out on all the great content on our Lisa's youtube channel. Youtube   Order Lisa's Books Lisa has published 5 books: Running Hot, Running to Extremes, Relentless, What your oncologist isn't telling you and her latest "Thriving on the Edge"  Check them all out at  https://shop.lisatamati.com/collections/books   Perfect Amino Supplement by Dr David Minkoff Introducing PerfectAmino PerfectAmino is an amino acid supplement that is 99% utilized by the body to make protein. PerfectAmino is 3-6x the protein of other sources with almost no calories. 100% vegan and non-GMO. The coated PerfectAmino tablets are a slightly different shape and have a natural, non-GMO, certified organic vegan coating on them so they will glide down your throat easily. Fully absorbed within 20-30 minutes! No other form of protein comes close to PerfectAminos Listen to the episode with Dr Minkoff here:    Use code "tamati" at checkout to get a 10% discount on any of their devices.   Red Light Therapy: Lisa is a huge fan of Red Light Therapy and runs a Hyperbaric and Red Light Therapy clinic. If you are wanting to get the best products try Flexbeam: A wearable Red Light Device https://recharge.health/product/flexbeam-aff/?ref=A9svb6YLz79r38   Or Try Vielights' advanced Photobiomodulation Devices Vielight brain photobiomodulation devices combine electrical engineering and neuroscience. To find out more about photobiomodulation, current studies underway and already completed and for the devices mentioned in this video go to www.vielight.com and use code “tamati” to get 10% off     Enjoyed This Podcast? If you did, subscribe and share it with your friends! If you enjoyed tuning in, then leave us a review and share this with your family and friends. Have any questions? You can contact my team through email (support@lisatamati.com) or find me on Facebook, Twitter, Instagram and YouTube. For more episode updates, visit my website. You may also tune in on Apple Podcasts.  To pushing the limits, Lisa and team

In this episode, Dr. Katie Fell (General Cardiology Fellow at University of Michigan and CardioNerds Academy Fellow) and Dr. Gurleen Kaur (incoming General Cardiology fellow at Brigham and Women's Hospital and Director of CardioNerds Internship) discuss with Dr. James Arrighi (General Cardiologist and CEO of ACGME-International) about developing as a clinician educator and the concept of competency-based education. The PA-ACC & CardioNerds Narratives in Cardiology is a multimedia educational series jointly developed by the Pennsylvania Chapter ACC, the ACC Fellows in Training Section, and the CardioNerds Platform with the goal to promote diversity, equity, and inclusion in cardiology. In this series, we host inspiring faculty and fellows from various ACC chapters to discuss their areas of expertise and their individual narratives. Join us for these captivating conversations as we celebrate our differences and share our joy for practicing cardiovascular medicine. We thank our project mentors Dr. Katie Berlacher and Dr. Nosheen Reza. The PA-ACC & CardioNerds Narratives in Cardiology PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Video version - Becoming a “Big E” Medical Educator as a Cardiologist with Dr. James Arrighi https://youtu.be/xcrwnz6_9Qg Quoatables - Becoming a “Big E” Medical Educator as a Cardiologist with Dr. James Arrighi “You really have to have a passion or a love for what you do...that's probably responsible for most of the success one has in life” (time 4:43) “Sub-subspecialty societies in Cardiology represent [a] great opportunity for junior faculty or even trainees to get involved, even before getting involved in ACC.” (time 5:30) “Competency-based medical education and time variable training are not synonymous.” (time 16:43) “As Cardiology evolves into more and more subspecialties...it begs the question... ‘Is Cardiology a primary specialty?'” (time 27:30) “We need to think about [a] more efficient ways for training.” (time 31:55) “As a clinician educator, there's variety, there's innovation!” (time 41:22) Notes - Becoming a “Big E” Medical Educator as a Cardiologist with Dr. James Arrighi How might one develop as a clinician educator on a national level? Junior faculty and trainees should consider taking advantage of education opportunities in various Cardiology sub-specialty societies (ex: American Society of Nuclear Cardiology, ASNC). This may include involvement in different committees. These opportunities are great ways to build connections and establish a reputation on a national level. This can help lead to other opportunities with larger national organizations (ex: ACC, AHA). Cardiology Training Oversight The Accreditation Council for Graduate Medical Education (ACGME) and American Board of Internal Medicine (ABIM) both have regulatory power over Cardiology training, providing the minimum clinical experience standards for Cardiology fellowship training programs.The ACGME oversees accreditation for Cardiology fellowships.The ABIM defines the requirements for eligibility for certification of individuals. Over time, the ACGME has transitioned to placing an emphasis on quality improvement, with a particular focus on continuous programmatic improvement. The American College of Cardiology (ACC) helps define more granular recommendations for Cardiology training programs and their curriculum.Periodically the ACC releases training guidelines for Cardiology fellowship programs, called Core Cardiovascular Training Statements, or COCATS. This document provides more contemporary, detailed, and specialty-specific recommendations for Cardiology training as compared to ACGME.While ACC has no regulatory authority over Cardiology training programs, COCATS documents provide a roadmap for program...

This episode represents 2 additional presentations from the October 25 live event titled' Real Talk on Men's Health.   In this Episode the following presentations are featured: Heart Health: Keep Your Heart Beating and Benign Prostatic Enlargement Guest:   Heart Health: Keep Your Heart Beating Dr Eugene Yang, MD,MS, FACC, Clinical Professor Department of Cardiology University of Washington School of Medicine. He is the Carl and Renee Behnke Endowed Professor for Asian Health and the Medical Director, UW Physicians Eastside Specialty Center as well as the Co Director UW Medicine Cardiovascular Wellness and Prevention Program.   Benign Prostatic Enlargement:   Dr Will Fuller, MD. Dr Fuller is an Attending Urologist, Virginia Mason Franciscan Health Urology During This Episode We Discuss:   Primary Risk Factors for Cardiovascular Disease Behavioral and lifestyle optimization of risk factors 2019 American College of Cardiology(ACC)  and American Heart Association (AHA)Prevention Guidelines The ACC ASCVD Risk Estimator Cholesterol Goals Blood Pressure Goals Lifestyle Recommendations Sodium and Blood Pressure Heart Healthy Diets Exercise and Heart Health   Prostate Anatomy Prostate Enlargement Symptoms Evaluation of Prostate Enlargement  Treatment options for Prostate Enlargement  

Interventional cardiologist Dan Sraow, MD, FACC discusses the election of a nurse rather than a physician to lead the American College of Cardiology (ACC), as well as the risks of non-physicians performing cardiac interventions.PhysiciansForPatientProtection.org

The following question refers to Section 4.3 of the 2021 ESC CV Prevention Guidelines. The question is asked by CardioNerds Academy Intern Dr. Maryam Barkhordarian, answered first by medicine resident CardioNerds Academy House Chief Dr. Ahmed Ghoneem, and then by expert faculty Dr. Kim Williams.Dr. Williams is Chief of the Division of Cardiology and is Professor of Medicine and Cardiology at Rush University Medical Center. He has served as President of ASNC, Chairman of the Board of the Association of Black Cardiologists (ABC, 2008-2010), and President of the American College of Cardiology (ACC, 2015-2016). The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. Question #27 Mr. O is a 48-year-old man with a past medical history significant for obesity (BMI is 42kg/m2), hypertension, type 2 diabetes mellitus, and hypercholesterolemia. His calculated ASCVD risk score today is 18.8%. You counsel him on the importance of weight loss in the context of CVD risk reduction. Which of the following weight loss recommendations is appropriate?AMaintaining a weight loss of at least 25% from baseline is required to influence blood pressure, cholesterol, and glycemic control. BHypocaloric diets lead to short term weight loss, but a healthy diet should be maintained over time to reduce CVD risk.CLiraglutide can be used to induce weight loss, as an alternative to diet and exercise.DBariatric surgery is effective for weight loss but has no ASCVD risk reduction benefit. Answer #27 Explanation The correct answer is B. Energy restriction is the cornerstone of management of obesity. All the different types of hypocaloric diets achieve similar short-term weight loss, but these effects tend to diminish by 12 months. It is a class I recommendation to maintain a healthy diet over time to achieve CVD risk reduction. The Mediterranean diet is an example of a diet that can have persistent CV benefit beyond the 12 months. Choice A is incorrect because maintaining even a moderate weight loss of 5 – 10% from baseline has favorable effects on risk factors including blood pressure, cholesterol, and glycemic control, as well as on premature all-cause mortality. Choice C is incorrect because medications approved as aids to weight loss (such as liraglutide, orlistat and naltrexone/bupropion) may be used in addition to lifestyle measures to achieve weight loss and maintenance; they are not alternatives to a healthy lifestyle. Meta-analysis of medication-assisted weight loss found favorable effects on BP, glycemic control, and ASCVD mortality. Choice D is incorrect because patients undergoing bariatric surgery had over 50% lower risks of total ASCVD and cancer mortality compared with people of similar weight who did not have surgery. Bariatric surgery should be considered for obese high-risk individuals when lifestyle change does not result in maintained weight loss (Class IIa). The ACC/AHA guidelines focused primarily on lifestyle interventions for obesity and had no specific recommendations for bariatric surgery or medication-assisted weight loss. Main Takeaway Weight reduction (even as low as 5-10% from baseline) and long-term maintenance of a healthy diet are recommended to improve the CVD risk profile of overweight and obese people. Medication and/or bariatric surgery may have a useful adjunctive role in some patients. Guideline Loc. Section 4.3.3 CardioNerds Decipher the Guidelines - 2021 ESC Prevention SeriesCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor RollCardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!

ACC.23 Congress Coverage

ACC.23 Congress Coverage

Confira os principais estudos e artigos abordados no congresso do American Collegy of Cardiology (ACC 2023), que aconteceu entre os dias 04 e 06 de #cardiologia #saúde #PEBMED #cobertura

GET MY FREE INSTANT POT COOKBOOK: https://www.chefaj.com/instapot-download ------------------------------------------------------------------------------------ MY LATEST BESTSELLING BOOK: https://www.amazon.com/dp/1570674086?tag=onamzchefajsh-20&linkCode=ssc&creativeASIN=1570674086&asc_item-id=amzn1.ideas.1GNPDCAG4A86S ------------------------------------------------------------------------------------ Monica Aggarwal, MD, FACC Director of Integrative Cardiology and Prevention Division of Cardiology University of Florida Monica Aggarwal, MD, is a Clinical Associate Professor of medicine in the University of Florida Division of Cardiovascular Medicine. She received her medical degree from Virginia Commonwealth University School of Medicine and subsequently went on to complete a residency in internal medicine at Tufts-New England Medical Center. She then completed a cardiology fellowship at the University of Maryland and later continued her training at the University of Arizona where she completed an integrative medicine fellowship. Dr. Aggarwal's own path to understanding the impact of nutrition in illness started soon after the birth of her third child, when she developed an advanced form of rheumatoid arthritis. She was placed on medications that gave her severe side effects. It was only through learning about the microbiome (gut), its impact on the immune system and the role of nutrition in affecting the gut, was she able to truly heal. Determined to change the face of medicine, Monica left private practice and returned to academics in order to pursue research on the role of diet and to create an integrative cardiology practice focused on nutrition and lifestyle. Serving as the Director of Integrative Cardiology and Prevention at the University of Florida, Dr. Aggarwal focuses on promoting food as the foundation of healing and for its medicinal value. In her clinic, she emphasizes plant based nutrition and often performs multiple mind-body techniques with her patients, including yoga and meditation. She is also the Director of Medical Education for Cardiology, where she directs education for medical residents and cardiology fellows, with a focus on prevention, nutrition and lifestyle. In the hospital, she has multiple initiatives including developing a 100% plant based menu for cardiac and vascular patients. Dr. Aggarwal gives talks around the community and the country. She was named a “Next Generation Innovator” by Cardiology Today. She is often featured in Veg News, Naked Magazine and has been featured in forksoverknives.com. She conducts research on nutrition education in medical institutions and on how a plant-based diet impacts cardiovascular disease. She has published in major medical journals such as Journal of American College of Cardiology and American Journal of Medicine. Board certified in cardiology, echocardiography and nuclear cardiology, she is a fellow of the American College of Cardiology (ACC), where she is a member of the nutrition council working on nutrition policies for the nation. Dr. Aggarwal specializes in preventative management of heart disease with lifestyle techniques in conjunction with medications. She is the author of the book “Body on Fire: How Inflammation Triggers Chronic Illness and the Tools We Have to Fight It,” which outlines prescriptions to help guide people to better health. She has instituted a new plant-based menu at the University of Florida/Shands Hospital which is receiving national attention along with new discharge education that empowers patients to heal their bodies with their lifestyles. She was recently named Florida's Cardiovascular Researcher of the year which provided her with a grant to conduct the important research needed on nutrition. You can get the book here: https://www.amazon.com/dp/1570673926?ref=exp_chefaj_dp_vv_d Website: https://www.drmonicaaggarwal.com/ Facebook: drmonicaaggarwal Twitter: @drmaggarwal Instagram: drmonicaaggarwal

For the 47th episode of the CIO podcast hosted by Healthcare IT Today, we sat down with Dr. Ami Bhatt, Chief Innovation Officer of the American College of Cardiology (ACC) to talk about her work in healthcare VR and innovation. First, we take a look at what the keys are to making a real difference […]

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yehuda Handelsman, MD The National Lipid Association (NLA) and the American College of Cardiology (ACC) recently provided recommendations to help us achieve optimal low-density lipoprotein (LDL) levels in statin-intolerant patients, but what other management strategies are available? Joining Dr. Charles Turck to answer this question and to give more key insights is Dr. Yehuda Handelsman, Medical Director and Principal Investigator at the Metabolic Institute of America.

Dr Dipti Itchhaporia, 70th President of American College of Cardiology (ACC), always met her fears with actions. One of her motivations to become a cardiologist was to be able to act in the face of acute situations. When Dr Itchhaporia, the fifth woman and the first of South Asian descent to fill in this position, was asked to summarise her presidential year, she answered: flourishing in opposition of languishing. Dr Ankur Kalra's guest in this episode of Parallax is Dr Dipti Itchhaporia, ACC Immediate-Past President, an interventional cardiologist and the Eric and Sheila Samson Endowed Chair in Cardiovascular Health, director of disease management for Hoag Heart and Vascular Institute, and associate professor at the University of California, School of Medicine. In this personal interview, Dr Itchhaporia recalls her early years and the influences and decisions that led her to medicine and cardiology. She talks about her connection to ACC and the importance of choosing a professional home where one can find their purpose under the mentorship of their community. Ankur asks Dr Itchhaporia about the most memorable moments of her presidency. They talk about South Asian identity and curbing CVD in this population. How does Dr Itchhaporia think about representation and the meaning of her historical position at ACC? What is Dr Itchhaporia's message to women in cardiology? Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest, @ditchhaporia hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

The following question refers to Section 4.3 of the 2021 ESC CV Prevention Guidelines. The question is asked by CardioNerds Academy Intern Dr. Maryam Barkhordarian, answered first by pharmacy resident Dr. Anushka Tandon and then by expert faculty Dr. Kim Williams. Dr. Williams is Chief of the Division of Cardiology and is Professor of Medicine and Cardiology at Rush University Medical Center. He has served as President of ASNC, Chairman of the Board of the Association of Black Cardiologists (ABC, 2008-2010), and President of the American College of Cardiology (ACC, 2015-2016). The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association. Question #15 Your patient mentions that she drinks “several” cups of coffee during the day. She also describes having a soda daily with lunch and occasionally a glass of wine with dinner. Which of the following recommendations is appropriate?  A. Coffee consumption is not harmful and may even be beneficial, regardless of the number of drinks per day. B. Drinking two glasses of wine/day is safe from a cardiovascular prevention standpoint. C. Soft drinks (and other sugar-sweetened beverages) must be discouraged. D. None of the above Listen to this podcast episode!  Answer #15 The correct answer is C.  Soft drinks (and other sugar-sweetened beverages) must be discouraged. Sugar-sweetened beverages have been associated with a higher risk of CAD and all-cause mortality. The ESC guidelines give a class I recommendation for restriction of free sugar consumption (in particular sugar-sweetened beverages) to a maximum of 10% of energy intake. This is a class IIa recommendation in the ACC/AHA guidelines. Choice A is incorrect because: the consumption of nine or more drinks a day of non-filtered coffee (such as boiled, Greek, and Turkish coffee and some espresso coffees) may be associated with an up to 25% increased risk of ASCVD mortality. Moderate coffee consumption (3-4 cups per day) is probably not harmful, and perhaps even moderately beneficial. Choice B is incorrect: It is a class I recommendation to restrict alcohol consumption to a maximum of 100 g per week. The standard drink in the US contains 14 g of alcohol, so 100 mg of alcohol translate to: o   84 ounces of beer (5% alcohol) o   Or 56 – 63 ounces of malt liquor (75% alcohol) or o   Or 35 ounces of wine (12% alcohol) or ONE 5 fl oz glass of wine/day. o   Or 31.5 ounces of distilled spirits (40% alcohol). The ACC/AHA guidelines recommended limiting alcohol consumption only for the management of hypertension to: ≤2 drinks daily for men and: ≤1 drink daily for women. Main Takeaway The main takeaway: ASCVD risk reduction can be achieved by restricting sugar-sweetened beverages to a maximum of 10% of energy intake. Guideline Location Section 4.3.2, Page 3271 CardioNerds Decipher the Guidelines - 2021 ESC Prevention Series CardioNerds Episode Page CardioNerds Academy Cardionerds Healy Honor Roll CardioNerds Journal Club Subscribe to The Heartbeat Newsletter! Check out CardioNerds SWAG! Become a CardioNerds Patron!

Monica Aggarwal, MD, is an adjunct Associate Professor in the University of Florida's Division of Cardiovascular Medicine where she conducts research on the impact of nutrition on chronic illness. She also serves as the Chief Medical officer of the not-for-profit, 4Roots Farm which is looking at how to improve food quality to improve human health. She received her medical degree from Virginia Commonwealth University School of Medicine and subsequently went on to complete a residency in internal medicine at Tufts University Hospital in Boston, MA. She then completed a cardiology fellowship at the University of Maryland in Baltimore, MD. Dr. Aggarwal's own path to understanding the impact of nutrition on illness started soon after the birth of her third child when she developed an advanced form of rheumatoid arthritis. She was placed on medications that gave her severe side effects. It was only through learning about the microbiome (gut), its impact on the immune system, and the role of nutrition in affecting the gut that was she able to truly heal. Determined to change the face of medicine, Monica left private practice and returned to academics in order to pursue research on the role of diet and to create an integrative cardiology practice focused on nutrition and lifestyle. Dr. Aggarwal served as the Director of Integrative Cardiology and Prevention at the University of Florida for 4 ½ years during which time she was promoted to Associate Professor of Medicine. At the University of Florida, she focused on promoting food as the foundation of healing and for its medicinal value. In her clinic, she emphasizes plant-based nutrition and often performs multiple mind-body techniques with her patients, including yoga and meditation. At the University of Florida, she was also the Director of Medical Education for Cardiology, where she directed education for medical residents and cardiology fellows, with a focus on prevention, nutrition, and lifestyle. In the hospital, she has multiple initiatives including developing a 100% plant-based menu for cardiac and vascular patients. Dr. Aggarwal gives talks around the community, country, and internationally. She was named a Next Generation Innovator by Cardiology Today. She is often featured in Veg News, Naked Magazine, and forksoverknives.com. She conducts research on nutrition education in medical institutions and on how a plant-based diet impacts cardiovascular disease. She has published in major medical journals such as the Journal of American College of Cardiology and the American Journal of Medicine. Board-certified in cardiology and three specialties of cardiology: echocardiography, nuclear cardiology, and advanced lipid management, she is a fellow of the American College of Cardiology (ACC), where she is a member of the nutrition council working on nutrition policies for the nation. Dr. Aggarwal specializes in the preventive management of heart disease with lifestyle techniques in conjunction with medications. She is the author of the book Body on Fire: How Inflammation Triggers Chronic Illness and the Tools We Have to Fight It, which outlines prescriptions to help guide people to better health, and the recently released Body on Fire Cookbook which provides whole food, healthy recipes to help implement change. She has instituted a new plant-based menu at the University of Florida/Shands Hospital which is receiving national attention along with new discharge education that empowers patients to heal their bodies with their lifestyles. She was recently named Floridas Cardiovascular Researcher of the year which provided her with a grant to conduct the important research needed on nutrition in 2019 and Exemplary Teacher of the Year in 2020. She currently sees patients in Orlando, Florida at AdventHealth and via telemedicine as part of Wholistic Cardiology and details can be found on her website. Website: Drmonicaaggarwal.com Facebook: drmonicaaggarwal Twitter: @drmaggarwal Instagram: drmonicaaggarwal

For the millions of US patients who go to an ER or medical office with chest pain every year, doctors have several options for screening. New national guidelines recommend a quick and non-invasive heart scan known as CCTA for stable chest pain. Our guests today are leading experts in the field of advanced cardiac imaging and discuss the history and many applications of this technology, which produces a 3D image of the heart and can be used to rule out several potentially deadly conditions. The updated guidelines come from the American College of Cardiology (ACC), American Heart Association (AHA), and other groups. Meet the experts Amar Shah, MD, is Northwell's chief of cardiac imaging Michael Poon, MD is director of advanced cardiac imaging, for Northwell's Western Region.

ACC 2022 congress coverage

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

Go online to PeerView.com/XXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What's new in the treatment of hypertrophic cardiomyopathy (HCM)? Hear what was presented at the 70th Annual Scientific Session and Expo of the American College of Cardiology (ACC 2022) from Dr. Milind Desai, as he shares the latest evidence on novel therapies for HCM and considers how these findings can improve outcomes for patients in your clinical practice. Upon completion of this activity, participants should be better able to: Identify the mechanism of action of cardiac myosin inhibitors for the treatment of HCM, Describe the benefits and limitations of current management strategies for patients with obstructive and nonobstructive HCM, Apply the current body of evidence for cardiac myosin inhibitors to improve outcomes and enhance quality of life in patients with obstructive and nonobstructive HCM, including as an alternative to septal reduction therapy.

No episódio de hoje do check-up semanal, o editor-chefe médico do portal PEBMED, Ronaldo Gismondi, comenta os principais destaques do American College of Cardiology (ACC 2022), congresso de cardiologia americano que aconteceu em abril de 2022, em Washington, D.C., nos Estados Unidos. O evento contou com a apresentação de mais de 30 estudos. Aperta o play e ouça agora o episódio!

The following question refers to Section 4.3 of the 2021 ESC CV Prevention Guidelines. The question is asked by CardioNerds Academy Intern Dr. Maryam Barkhordarian, answered first by medicine resident CardioNerds Academy House Chief Dr. Ahmed Ghoneem, and then by expert faculty Dr. Kim Williams. Dr. Williams is Chief of the Division of Cardiology and is Professor of Medicine and Cardiology at Rush University Medical Center. He has served as President of ASNC, Chairman of the Board of the Association of Black Cardiologists (ABC, 2008-2010), and President of the American College of Cardiology (ACC, 2015-2016). The CardioNerds Decipher The Guidelines Series for the 2021 ESC CV Prevention Guidelines represents a collaboration with the ACC Prevention of CVD Section, the National Lipid Association, and Preventive Cardiovascular Nurses Association. Question #3 Mrs. B is a 56-year-old African American woman with a past medical history significant for type 2 diabetes (HbA1C 7.6) and hypercholesterolemia. Her calculated ASCVD risk score today is 12.5% and her BMI is 24kg/m2. She is concerned about her high cholesterol levels despite being on a statin and feels that her diet is “not healthy enough.” She is interested in making dietary changes to help reduce her ASCVD risk. Which of the following recommendations is appropriate?A. Sodium restriction to

Startup Messaging – Cardiologist POV! This week, your Message Engineer Podcast host, Maureen Shaffer (CEO of Mingletoe LLC), sits down with David Lee Scher, MD, who has been a cardiologist for 30 years. Dr. Scher is the former 20-year Director of Electrophysiology at the University of Pittsburgh Medical and presently at Lancaster General Health/Penn Medicine. He has served on executive committees for the Pennsylvania Chapter of the American College of Cardiology (ACC), cardiology representative for a Medicare Carrier Advisory Board, and IT Committee of the Heart Rhythm Society (HRS) as well as serving as Chair of the HIMSS mHealth Roadmap Task Force.Dr. Scher shares myriad insights spanning brand awareness, Artificial Intelligence, remote monitoring, home health care services, and more. Tune in to hear key takeaways, including: The role social media plays in awareness as well as marketing and salesShifting the narrative from “time is money” to “time is sanity” to prevent burnoutArtificial Intelligence (AI) and its potential in discharge planning and with payersThe value of expanding remote patient monitoring to include environmental monitoring & much, much more!Listen to the full episode on the Message Engineer Podcast everywhere!Watch full video episode: https://www.youtube.com/channel/UCGhobfgJvoXc3Ex9R6oVFBA  Follow Maureen Shaffer: https://www.linkedin.com/in/maureenashaffer       Follow David Lee Scher, MD, FACP, FACC, FHRS, FESC: https://www.linkedin.com/in/davidleescher and on Twitter at @dlschermd______________________________More... on David Lee Scher, MDDr. Scher was a pioneer in digital health technology as the first physician in private practice to perform remote monitoring of implantable defibrillators as a clinical investigator in 2000 as well as the integration of that data into an electronic health record. He chaired the Blue-Ribbon Panel of Happtique which developed standards for its certification program of health and medical apps in 2012.  Scher has served as a consultant to many medical device and digital health technology companies. His breadth of clinical and consulting experiences gives him a unique perspective on the developing landscape in the digital health tech industry.  Scher has been featured in national and international print as well as online sites providing education and advice about mobile and other digital health technologies. His internationally awarded blog The Digital Health Corner is a comprehensive primer of digital health landscape, strategy, and advocacy.  Scher lectures nationally and internationally to professional and public audiences on the topic of digital health technologies, which, because of constraints of healthcare systems worldwide, will become a critical aspect of preventive, diagnostic, and therapeutic medicine. Developing strategies for mobile health is an imperative for which Scher is proud to advocate. 

This MedAxiom HeartTalk explores recent TVT Registry data on racial and socioeconomic disparities in structural heart programs, such as TAVR. Host Melanie Lawson talks with Wayne Batchelor, MD, Inova Health, Kimberly Guibone, DNP, Beth Israel Deaconess Medical Center, and Joan Michaels, RN, of the American College of Cardiology. They examine some possible reasons for these disparities and a few strategies CV programs can use to bridge this gap.Guest Bios:Kimberly Guibone, DNP, ACNP- BC, FACCDr. Guibone is the Structural Heart Clinical Program Manager at Beth Israel Deaconess Medical Center in Boston, MA and has led the Structural Heart program there since its inception and early clinical trials. She did her graduate work at Georgetown University in Washington, DC and completed her doctoral studies in Nurse Executive Leadership at Simmons University in Boston, MA. She is currently a member of the ACC/STS TVT Registry Steering Committee and the ACC Lifelong Learning Oversight Committee. Her areas of interest include enhancement of the advanced practitioner role, disparities in healthcare, development of the heart team, and clinician burnout.Joan Michaels, RN, MSN, CPHQ, AACCMs. Michaels is Director of Cardiac Registries for the American College of Cardiology. She has been with the ACC for more than 13 years and is the Program Manager for the STS/ACC TVT Registry. Ms. Michaels is a registered nurse with extensive experience working in the cardiovascular area. Prior to working at ACC, she held several management positions at Inova Fairfax Hospital in Falls Church, Va. Most recently, she was the Director of the NIH Cath Lab at Suburban Hospital in Bethesda, Maryland. Ms. Michaels received her BSN from the University of Pennsylvania, Philadelphia, Pennsylvania and her MSN from The Catholic University of America, Washington, DC.Wayne Batchelor, MD, MHS, FSCAI Born in Kingston, Jamaica, West Indies, Dr. Batchelor grew up in Kingston, Ontario, Canada, where he graduated class valedictorian from Frontenac Secondary High School. In 1990, he received a Bachelor of Arts and Medical Degree from Queen's University in Kingston, Ontario, Canada and was the recipient of the Dr. and Mrs. Sydney P. Schiff Medal in Surgery and the Nathan E. Berry Prize in Urology. He furthered his post-graduate medicine training by completing a Comprehensive Internal Medicine Residency and Fellowship in Adult Cardiology at the University of Toronto (UOT), where he received the University of Toronto Sopman Award for Clinical Excellence and Human Compassion. Upon completing a Cardiology Fellowship at the UOT, he was awarded a National Research Fellowship from the Heart and Stroke Foundation of Canada, which took him to Duke University, where he received a Master's of Health Science Degree and completed a 3-year Research Fellowship at the Duke University Clinical Research Institute under the supervision of Professor Robert Califf (incoming FDA Commissioner). During this time, he also completed an Advanced Fellowship in Interventional Cardiology. Thereafter, Dr. Batchelor returned to Toronto, where he served as an Assistant Professor of Medicine, Interventional Cardiologist and Clinician Investigator in the Department of Medicine at the University of Toronto (St. Michael's Hospital). In 2002, he moved to the US and was hired by Southern Medical Group, PA, in Tallahassee, Florida. There, he co-founded the Tallahassee Research Institute (TRI), a broad-based independent cardiovascular clinical research institute, which rapidly grew to be the most active research program in Florida's Panhandle. He joined the Medical Faculty at the Florida State University College of Medicine and was promoted to Adjunct Associate Professor of Medicine. In Tallahassee, Florida, he held numerous Executive Leadership positions, including Chair of the Tallahassee Memorial Healthcare Medical Staff Executive Committee (2009-2010), President of Southern Medical Group, PA, President of TRI, and served on the Tallahassee Memorial Healthcare Board of Trustees. He currently holds numerous leadership positions within national and international cardiology organizations, including Chair of the American College of Cardiology's (ACC) Interventional Sectional Leadership Council, Program Committee Member for the 2021 ACC/World Congress of Cardiology Scientific Sessions, Member of the Scientific Program Committee of the Transcatheter Cardiovascular Therapeutics (TCT) Meeting and active Member of the NCDR STS/TVT Registry's Steering Committee. He also currently serves as President of the Duke University Cardiovascular Cooperative Society (DUCCS) and is past President of the South Atlantic Cardiovascular Society (SACS). Dr. Batchelor was instrumental in developing one of the most advanced and innovative interventional cardiology and structural heart programs in Florida and was the first physician in the region to perform transradial percutaneous coronary intervention (PCI). In 2011, Dr. Batchelor led North Florida's first Structural Heart Program and soon thereafter performed the region's first transcatheter mitral valve repair and transcatheter aortic valve replacement (TAVR) procedures. For over 15 years, he provided the region's primary clinical leadership and research within interventional cardiology. Dr. Batchelor has published over 140 original abstracts/manuscripts, multiple book chapters and has given hundreds of invited lectures. He has overseen and/or participated in over 170 clinical trials, including being Principal Investigator in over 75. He also founded the Florida Institute for Medical Education (FIME), a corporation focusing on educating interventional cardiologists on new innovative procedures and promoting research. He has served on several international clinical trial steering committees and was the National Co-Principal Investigator for the PLATINUM DIVERSITY study, which is the first to prospectively evaluate clinical outcomes and socioeconomic status in minorities and women after contemporary coronary stent procedures in 52 sites across the United States. In March 2017, Dr. Batchelor was recognized by his physician peers in North Florida as the Capital Medical Society's Outstanding Physician of the Year. In 2019, Dr. Batchelor was hired by the Inova Health System in Falls Church, Virginia, to serve as the Director of Interventional Cardiology, Directory of Interventional Cardiology Research, Education and Innovation and Associate Director of the Inova Heart and Vascular Institute. As such, he heads up a large interventional cardiology program within Inova's $5 billion health system that spans five metropolitan hospitals and is responsible for the executive leadership clinical, research and educational efforts within the health system's Interventional Cardiology Program. In 2022, he was appointed as the Chair of the Interventional Leadership Council of the American College of Cardiology (ACC), representing over 5,000 interventional cardiology members nationally and internationally. He has also recently been appointed as a special government employee and consultant to the US Food and Drug Administration (FDA) within the Cardiovascular Devices Branch and has served on the Circulatory System Device panel. Dr. Batchelor is board-certified in Cardiovascular Diseases with added qualifications in Interventional Cardiology and enjoys traveling, playing tennis, and spending time with his wife Zaneta and two children, Nadia and Samia.

Today I'm speaking with Dr. Nitesh Sood, an electrophysiologist who is board-certified in internal medicine and holds certifications in echocardiography, nuclear medicine, and cardiovascular disease. Dr. Sood is currently the Director of the Atrial Fibrillation Wellness Program at Southcoast Physicians Group in Dartmouth, Massachusetts.Dr. Sood was selected as “Star Fellow” “Fellow Elite in Training” 2012 by the American College of Cardiology (ACC) and also “Young Investigator of the year” 2012. Dr. Sood has a special interest in treating patients with atrial fibrillation, syncope, and implantation of pacemakers and implantable cardioverter-defibrillators.Sood was the first electrophysiologist to utilize pulse-field ablation and has now completed 33 procedures using PFA for atrial fibrillation, more than any other physician in the world at this point. Join us for a discussion on the use of pulse-field ablation, and its many advantages over cryo or radiofrequency ablation.Discussion points:Introduction and background – Dr. Nitesh SoodWhy PFA and how has cryo ablation progressed over timePFA is very young, has only existed for about 20 yearsApoptosis vs. necrosis in ablation proceduresWhat structures may be at risk when performing ablationAnimal studies have shown that PFA causes minimal damage in many at-risk areasPFA has potential for temporary nano-pores that can be useful for delivering medicine such as those used for cancer treatmentMRI data shows incredible cell recovery 3 mos. After PFA, vs. radiofrequency ablationThe length of time needed for PFA is much shorter than cryo or radio, thus minimizing risks of time under anesthesiaThe learning curve for PFA is around 4-5 casesOther uses and some minimal risks of PFAAfib is on the increase, partly due to more monitoring and tests being availableAfib can easily be monitored by patients themselves, with things like Fitbit and Apple watches, to help doctors treat them more effectivelyTake a look at our website ClubAfib.com to find out more and track your own Afib– give us your feedback!Resources:Dr. Nitesh Sood at Southcoast Physicians GroupDr. Nitesh Sood LinkedInClubAfib.com WebsiteDr. Kiankhooy LinkedInAll Things AFib WebsiteAll Things AFib TwitterAll Things AFib YouTube Channel

Management of heart failure (HF) has evolved over the past few years, prompting the American College of Cardiology (ACC) to release a 2021 Update to Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment to provide guidance and recommendations on clinical care of HF patients with a reduced ejection fraction (HFrEF). New therapies for HFrEF have emerged that expand the arsenal for this patient population, particularly angiotensin receptor-neprilysin inhibitors (ARNI) and sodium glucose cotransporter-2 (SGLT2) inhibitors. However, use of guideline directed medical therapy (GDMT) is still suboptimal, and there is a need for pharmacists to assist in improving medication adherence. This podcast episode provides general practitioners an update on new evidence for pharmacotherapy and provides guidance on how to initiate GDMT in patients with HFrEF successfully in both inpatient and outpatient settings.      The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Coffee and Cardiology with Interventional Cardiologist Dr. Jamie McCabe to talk about what it takes to complete 150 mitraclip procedures, redefining how outcomes are measured, what leadership means to him and his crossroads between furniture making and medicine.2:57 - Mitraclip5:30 - Structural Heart Team7:05 - Dynamics of multidisciplinary teams9:40 - Volumes (Both sides)16:40 - TAVR Returns19:00 - TAVR Patient Selection 22:10 - Physician Report Cards25:00 - Risk Treatment Paradox29:40 - Leadership philosophy 33:45 - Vision of the Cath lab37:23 - Impact of Covid41:06 - Outside of the Lab42:43 - The furniture maker?49:08 - The pinnacle of structural heartDr. James (Jamie) McCabe grew up in Boston, Massachusetts, graduated magna cum laude from Bowdoin College and received his medical degree from Yale University. He has completed 10 years of post-medical school training including internal medicine training and general cardiology fellowship at University of California, San Francisco (UCSF) and interventional cardiology fellowship as well as an advanced interventional fellowship in structural and peripheral treatments at Brigham and Women's Hospital / Harvard Medical School. He is board certified in Internal Medicine, Cardiology, and Interventional Cardiology.Dr. McCabe joined the University of Washington Medical Center in 2013. He became medical director of the Cardiac Cath Labs in 2015 and subsequently was named Chief of Interventional Cardiology for the UW System in 2020. His clinical practice leverages his knowledge and experience in clinical cardiovascular medicine and complex coronary and valvular heart interventions. Dr. McCabe is an international leader in structural heart interventions including repair or replacement of all heart valves using catheter-based methods. He also treats all forms of coronary artery blockage and cardiogenic shock. He is an internationally recognized clinician educator and investigator in transcatheter therapies for valvular heart disease. His research interests focus on quality and performance metrics for cardiovascular procedures and novel transcatheter therapies to address unmet needs in the structural heart space. He has been the site principal investigator for dozens of clinical trials and has authored more than 100 original manuscripts and multiple book chapters related to his work. He lectures frequently at national and international meetings including at Transcatheter Cardiovascular Therapeutics (TCT), Trancatheter Valve Therapeutics (TVT), American College of Cardiology (ACC) and Society for Cardiac Angiography and Intervention (SCAI), amongst others. He has also been asked to perform live televised procedures for national and international audiences across multiple continents. He has been recognized as an Emerging Leader in Medicine by SCAI and the ACC, named one of three finalists for the Linnemeier Award, and voted a “Top Doc” in cardiology multiple years in a row by Seattle Magazine and Seattle Met Magazine.To reach Dr. Jamie McCabe you can email him at jmmccabe@uw.edu.Or send a referral or consult request here:  https://hipaa.jotform.com/uwheart/referrals

In this episode, we celebrate 20 years of transforming cardiovascular care, together. From physician-hospital integration, to major legislative reform, to a global pandemic, the MedAxiom community, alongside the American College of Cardiology (ACC), has always found a way to meet the challenge of the day, pushing the needle towards innovation. On MedAxiom HeartTalk, host Melanie Lawson sits down with a powerhouse panel, who have been there since the start: Ed Fry, MD, FACC, Cathie Biga, MSN, RN, FACC, and Jerry Blackwell, MD, MBA, FACC. They discuss how it all began, the impact of collaboration, and their thoughts on what the future holds.Guest Bios:Jerry Blackwell, MD, MBA, FACC, is President and CEO of MedAxiom. Blackwell graduated from Marshall University's Joan C. Edwards School of Medicine and completed residency/chief residency/fellowship at the Ohio State University and the University of Alabama - Birmingham. He earned his executive MBA from the University of Tennessee. He has more than 30 years of experience in cardiovascular medicine including academic cardiology, private practice and large integrated cardiovascular group leadership. Most recently, he served as executive vice president and chief clinical officer of the Ballad Health System.Blackwell has a passion for physician leadership, teaching, and care transformation - particularly team-based care and organizational performance improvement. He maintains a clinical practice with special interests in advanced imaging, including cardiovascular magnetic resonance imaging, cardiovascular CT angiography, and cardiac positron emission tomography.Blackwell has been involved with both MedAxiom and the American College of Cardiology for many years. He has served on the ACC's Board of Governors, the board of directors for the Cardiology Advocacy Alliance, and the ACC's Health Affairs Committee.Ed T.A. Fry, MD, FACC, is Chair of Ascension Health Cardiovascular Service Line and Vice President of the ACC. Fry attended medical school at Washington University School of Medicine in St. Louis and completed his residency in internal medicine at Barnes-Jewish Hospital. He completed a two-year cardiovascular research fellowship focused on pharmacokinetics/pharmacodynamics of native and genetically modified plasminogen activators. He also completed a general cardiology fellowship at Washington University, where he then served as assistant professor and medical director of the cardiac transplant program before completing an interventional cardiology fellowship at Ascension St. Vincent Hospital – Indianapolis.In 1991, he joined the cardiology practice at St. Vincent where he continues to be a busy interventional and general cardiologist and serves as chair of the Ascension National Cardiovascular Service Line. He helped launch Navion Healthcare Solutions, a subsidiary data quality management software company owned by Ascension, where he previously served as board chair.Fry is past president and governor of ACC's Indiana Chapter. Within the ACC, he has served on the Audit and Compliance Committee (Chair), Digital Strategy Steering Committee; Interventional Section Leadership Council; Surviving MI Initiative; Integrating the Health Enterprise Health Policy Work Group; Clinical Quality Committee; Prior Authorization Work Group; ACC Telemedicine Project; ACC COVID-19 Hub; Board of Governors Steering Committee; Innovations Development Work Group; ACC Premier Oversight Work Group (chair); Board of Trustees (BOT) Task Force on Clinician Well-Being; Health Systems Task Force; ACC/AHA Ethics and Professionalism Consensus Task Force, and ACC Nominating Committee. He has been a presenter, moderator and session chair at ACC Annual Scientific Session, ACC CV Summit, MedAxiom CV Transforum, Heart House Roundtables and is a member of HeartPAC, ACC's political action committee. He currently serves on ACC's BOT.Cathie Biga, MSN, RN, FACC, is President and CEO of Cardiovascular Management of Illinois, a cardiology physician practice management company. She works with more than 100 providers in the Chicago, IL, area and partners in their cardiovascular service lines at more than 14 acute care hospitals. She earned her Bachelor of Science degree in nursing from the Mayo/College of St. Teresa and Master of Science in nursing at Northern Illinois University School of Nursing.Biga has more than 40 years of experience as a registered nurse, service line director, hospital vice president and CEO. She has 20 years of experience in physician practice management.She has been active nationally in consulting in strategic planning, operational efficiencies, integrated financial and quality initiatives, and growth and development of the cardiovascular service lines. She is focused on facilitating the integration of strategic, financial and quality perspectives between cardiovascular service lines at practices and hospitals. In addition, she consults and lectures on numerous contemporary cardiovascular topics.Biga is a member of ACC's Board of Trustees, Chair of the MedAxiom Board of Managers, a member of the American Association of Cardiovascular and Pulmonary Rehabilitation and an ACC Fellow.

In this week's episode, Mary shares her experience participating in a patient forum, hosted by the Hypertrophic Cardiomyopathy Association (HCMA) and the American College of Cardiology (ACC), while Alex speaks to how we can transfer the knowledge, information, and lessons learned from such experiences to real life and living every day with diseases and complex medical conditions. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Aperte o play e percorra os principais resultados dos estudos mais relevantes apresentados nas sessões científicas do American College of Cardiology (ACC) 2021 com os comentários dos Drs. Bruno Valdigem, Álvaro Avezum e Alexandre Soeiro.

Dr Nanette K.Wenger, M.D., M.A.C.C., M.A.C.P., FAHA is Professor of Medicine ( Cardiology ) at the Emory University School of Medicine apart from being the founding consultant to Emory Women's Heart Centre, Atlanta, USA. She is an ICON having contributed extensively to research in coronary heart disease in Women, Preventive and Geriatric Cardiology. Dr Wenger has received innumerable prestigious awards including outstanding professional achievement award from Hunter College (1993), James D.Bruce Memorial award of American College of Physicians (2000), a distinguished fellow award from the Geriatric Society of Cardiology (2002), Gold Heart Award of the American Heart Association (AHA) (2004), Lifetime achievement award of Georgia Chapter of the American College of Cardiology (ACC) (2009), James B.Herrick Lecture of the AHA (2011), distinguished Mentor Award of the ACC(2013), Bernadine Healy Leadership of ACC (2015), and outstanding Alumna award from the Emory Alumni Association (2019). Professor Wenger is an author of several ACC, AHA guidelines and has authored or co-authored over 1600 scientific publications. She is listed in BEST DOCTORS IN AMERICA.

Dr Nanette K.Wenger, M.D., M.A.C.C., M.A.C.P., FAHA is Professor of Medicine ( Cardiology ) at the Emory University School of Medicine apart from being the founding consultant to Emory Women's Heart Centre, Atlanta, USA. She is an ICON having contributed extensively to research in coronary heart disease in Women, Preventive and Geriatric Cardiology. Dr Wenger has received innumerable prestigious awards including outstanding professional achievement award from Hunter College (1993), James D.Bruce Memorial award of American College of Physicians (2000), a distinguished fellow award from the Geriatric Society of Cardiology (2002), Gold Heart Award of the American Heart Association (AHA) (2004), Lifetime achievement award of Georgia Chapter of the American College of Cardiology (ACC) (2009), James B.Herrick Lecture of the AHA (2011), distinguished Mentor Award of the ACC(2013), Bernadine Healy Leadership of ACC (2015), and outstanding Alumna award from the Emory Alumni Association (2019). Professor Wenger is an author of several ACC, AHA guidelines and has authored or co-authored over 1600 scientific publications. She is listed in BEST DOCTORS IN AMERICA.

This week’s View goes over key perspectives from the 2020 American College of Cardiology (ACC) and American Heart Association (AHA) guideline for the management of patients with valvular heart disease, which replaces the ACC/AHA 2014 guideline and the 2017 focused update.

O conhecimento e a evolução da ciência são dinâmicos!É fundamental revisarmos e entendermos as mudanças propostas por guidelines e diretrizes das sociedades médicas a respeito dos mais diferentes assuntos.Hoje vamos discutir um tema de extrema importância e muito prevalente na prática clínica diária: o Infarto Agudo do Miocárdio (IAM), mais especificamente, o IAM sem supradesnivelamento do seguimento ST.Vamos revisar conceitos reforçados por diversas entidades como a European Society of Cardiology (ESC), o American College of Cardiology (ACC) e a American Heart Association (AHA).Além disso, para discutir e esclarecer as atualizações da ESC de 2020 contaremos com a participação especial da Dra. Gabriela Miana, especialista em clínica médica pelo HC-UFMG, cardiologia pelo Instituto Dante Pazzanese e arritmologia pelo INCOR-USP.Fique por dentro das novas atualizações sobre estratificação de risco, indicações de estudos invasivos e recomendações sobre o uso de antiplaquetários!Não se esqueça que é sempre importante contextualizar a nossa conduta de acordo com o serviço em que trabalhamos.Não perca esse bate-papo incrível!

Monica Aggarwal, MD, is an associate professor of medicine in the University of Florida Division of Cardiovascular Medicine. Serving as the Director of Integrative Cardiology and Prevention at the University of Florida, Dr. Aggarwal focuses on promoting food as the foundation of healing and for its medicinal value. She is also the Director of Medical Education for Cardiology, where she directs education for medical residents and cardiology fellows, with a focus on prevention, nutrition and lifestyle. In the hospital, she has multiple initiatives including developing a 100% plant based menu for cardiac and vascular patients.Dr. Aggarwal gives talks around the community and the country. She was named a “Next Generation Innovator” by Cardiology Today. She is often featured in Veg News, Naked Magazine and has been featured in forksoverknives.com. She conducts research on nutrition education in medical institutions and on how a plant based diet impacts cardiovascular disease.Board certified in cardiology, echocardiography and nuclear cardiology, she is a fellow of the American College of Cardiology (ACC), where she is a member of the nutrition council working on nutrition policies for the nation. Monica specializes in preventative management of heart disease with lifestyle techniques in conjunction with medications. She is the author of the book “Finding Balance: Empower Yourself with Tools to Combat Stress and Illness,” which outlines 10 prescriptions to help guide people to better health.

COVID-19 causes STEMI’s, arrhythmias and myocarditis?!? Emergency medicine and cardiology guru Amal Mattu, MD chats with Mizuho Morrison, DO on the cardiovascular effects of COVID-19. They discuss: the known pathophysiology of how viral infections affect the heart; Review the new consensus statement from the Society of Cardiovascular Angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) on how to manage STEMIs; and lastly discuss how cardiac arrest management differs in this COVID era.    To view the references and show notes from this podcast Click here

COVID-19 causes STEMI’s, arrhythmias and myocarditis?!? Emergency medicine and cardiology guru Amal Mattu, MD chats with Mizuho Morrison, DO on the cardiovascular effects of COVID-19. They discuss: the known pathophysiology of how viral infections affect the heart; Review the new consensus statement from the Society of Cardiovascular Angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) on how to manage STEMIs; and lastly discuss how cardiac arrest management differs in this COVID era.    To view the references and show notes from this podcast Click here

COVID-19 causes STEMI’s, arrhythmias and myocarditis?!? Emergency medicine and cardiology guru Amal Mattu, MD chats with Mizuho Morrison, DO on the cardiovascular effects of COVID-19. They discuss: the known pathophysiology of how viral infections affect the heart; Review the new consensus statement from the Society of Cardiovascular Angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) on how to manage STEMIs; and lastly discuss how cardiac arrest management differs in this COVID era.    To view the references and show notes from this podcast Click here

COVID-19 causes STEMI’s, arrhythmias and myocarditis?!? Emergency medicine and cardiology guru Amal Mattu, MD chats with Mizuho Morrison, DO on the cardiovascular effects of COVID-19. They discuss: the known pathophysiology of how viral infections affect the heart; Review the new consensus statement from the Society of Cardiovascular Angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP) on how to manage STEMIs; and lastly discuss how cardiac arrest management differs in this COVID era.      Promo code for 3 month trial of ERcast in intro segment Hippo education COVID resource site: Link   References:  Mahjid, M. Payam, S. et al. Potential Effects of Coronaviruses on the Cardiovascular System: A Review [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. PMID 32219363 Mahmud E, Dauerman HL, et al.  Management of Acute Myocardial Infarction During the COVID-19 Pandemic,CONSENSUS STATEMENT from the Society of cardiovascular angiography and interventions (SCAI), American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP). Journal of the American College of Cardiology (2020), doi https://doi.org/10.1016/j.jacc.2020.04.039. PMID:32330544 Edelson D, Sasson C. et al. Interim Guidance for Basic and Advanced Life support in Adults, Children and Neonates with suspected or confirmed COVID-19. Circulation AHA April 2020. PMID: 32270695 Stefanini GG, Azzolini E, et al. Critical Organizational Issues for Cardiologists in the COVID-19 Outbreak: A Frontline Experience From Milan, Italy [published online ahead of print, 2020 Mar 24]. Circulation 2020. PMID: 32207994

O congresso virtual do American College of Cardiology (ACC 2020) aconteceu no início do mês e acompanhamos aqui, no Portal PEBMED, trazendo as principais novidades apresentadas. Nele, diversos estudos interessantes foram divulgados e, por isso, reunimos todos em um e-book gratuito. Mas, além disso, nosso editor-chefe médico, o cardiologista Ronaldo Gismondi, decidiu trazer também os principais pontos do ACC 2020 em um podcast especial! Confira! Você que é ouvinte dos podcasts da PEBMED tem um desconto de 20% no Whitebook! Baixe o aplicativo e insira o cupom PEBPODCAST no pagamento da assinatura.

No episódio de hoje do Check-up Semanal, nosso editor-chefe médico, Ronaldo Gismondi, traz as principais atualizações sobre a pandemia de coronavírus e as novidades apresentadas no congresso virtual do American College of Cardiology (ACC 2020), que termina hoje, 30. Os temas abordados no podcast sobre coronavírus foram: uso da cloroquina em casos moderado a graves, testes rápidos para identificação, e intubação traqueal e parada cardiorrespiratória. Das novidades do ACC 2020 temos: novo medicamento para insuficiência cardíaca com fração de ejeção reduzida (ICFER), uso da rivaroxabana em pequenas doses e oclusões coronarianas crônicas. Confira:

In this week's View, guest host Dr. Deepak Bhatt offers a preview of some of the hottest trials at ACC's Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) Virtual, taking place online only March 28-30, including VICTORIA, VOYAGER PAD, COMPASS, TAILOR PCI, SPYRAL HTN-OFF MED PIVOTAL, TWILIGHT, TICO, E3, REDUCE-IT, and ISCHEMIA.

NOW TRENDING ON ICONICLIFE.COM ICONIC HAUS...NOW VIRTUAL ICONIC HAUS The Heart Center at Phoenix Children’s Hospital is the beneficiary of ICONIC HAUS 2020  proceeds, and I talked with him about ten days ago before the coronavirus news intensified this week. As Co-Director of The Heart Center, Dr. Franklin shared the latest initiatives and innovative research coming out of The Heart Center, and why our support matters. Following my interview with Dr. Franklin, dear friend and father Justin Lee, owner of Moving Team Six and ICONIC HAUS sponsor, shares his personal story of how PCH saved his daughter’s life, and why he always says “yes” to Phoenix Children’s Hospital. Dr. Wayne Franklin Dr. Wayne Franklin is a graduate of Williams College in Williamstown, Massachusetts, and UCLA School of Medicine.  He did his residency training in Internal Medicine and Pediatrics at Duke University, where he first was exposed to Adult Congenital Heart Disease (ACHD).  He then did two simultaneous fellowships in adult cardiology and pediatric cardiology at St. Luke’s/Texas Heart Institute and at Baylor College of Medicine (BCM)/Texas Children’s Hospital (TCH) in Houston. In 2004, he founded the Texas Adult Congenital Heart Program, where he has served as Director from 2004-2018.  In 2013, he was appointed Chief of Cardiology at the TCH Pavilion for Women, where he directed the clinical and administrative cardiovascular service lines. In September of 2017, he was selected as Head of the Department Adult Medicine at Texas Children's Hospital and Associate Vice Chair of Clinical Operations in the Department of Pediatrics.  He is also the recipient of two prestigious Fulbright and Jaworski Awards of BCM Faculty Excellence, one in Teaching and one in Educational Leadership.  He came to Phoenix in 2018 to join Phoenix Children’s Hospital as the Co-Director of the Heart Center, the Director of the ACHD Program, and Chair of the Department of Adult Medicine.  In addition, he is a Full Professor in three University of Arizona-College of Medicine-Phoenix Departments, including the Departments of Medicine, Child Health, and Obstetrics and Gynecology.   Since his arrival, Dr. Franklin has transformed the care of adults with congenital heart disease in the Valley, and he has put together a team of experts in the field.  Phoenix Children’s Hospital is now undergoing accreditation to become the first hospital in Arizona to be accredited to comprehensive care of patients with adult congenital heart disease From an academic perspective, he is involved with several research projects on adults with congenital heart disease, specifically in patients with single ventricle-Fontan physiology, neurocognitive outcomes, pulmonary hypertension, cardiac disease in pregnancy, and most recently, transition medicine.  Dr. Franklin has been appointed to several medical advisory boards in congenital heart disease, including the Adult Congenital Heart Association (ACHA), the Alliance for Adult Research in Congenital Cardiology (AARCC), and American College of Cardiology (ACC). Since 2018, he has been the Co-Director of the Heart Center at Phoenix Children’s Hospital.  He has been an invited lecturer across North America, Europe, South America and South Asia.  He has offices in Central Phoenix, Scottsdale, Gilbert and Glendale.  In his off-time, Dr. Franklin likes to spend time with his two children and his wife, Rachel McNeill, anchor at 12 News/NBC-Phoenix. He remains a full-time husband, a lifetime father and a part-time golfer.   LINKS/RESOURCES Follow ICONIC LIFE digital luxury lifestyle magazine Instagram @youriconiclife Facebook @youriconiclife Twitter @youriconiclife   Check out ICONIC LIFE at ICONICLIFE.COM for fresh content published daily.  We invite you to SUBSCRIBE!   Follow Renee Dee Instagram @reneeldee  Twitter @iconicreneedee LinkedIn @ Renee Layman Dee If you enjoyed today’s podcast, I’d be so appreciative if you’d take two minutes to subscribe, rate and review ICONIC HOUR. It makes a huge difference in our growth. Thank you so much for supporting me to do what I do!

“Nowhere in this do I see that a low-carb, high-fat diet is detrimental to your health.” – Jimmy Moore There’s a sophisticated underground movement currently afoot seeking to discredit the low-carb, high-fat, ketogenic diet and promote a plant-based way of eating by some very powerful nutritional health forces with a variety of special interests involved. When it’s the American Heart Association (AHA) and the American College of Cardiology (ACC), this is a big freakin’ deal. Health podcaster and international bestselling author of KETO CLARITY Jimmy Moore shares about the new 2019 “Lifestyle Guidelines” from the AHA/ACC that tend to be a precursor to the new Dietary Guidelines for Americans set to be revealed in 2020. Listen to find out how they are equating a red meat, saturated fat, keto nutritional approach with a high sugar, high-carbohydrate, refined grain-based diet in this episode. Today we have a special JIMMY RANTS on The LLVLC Show for you. Jimmy is on his much deserved six-month sabbatical so we are bringing you some of the best content from Jimmy’s daily show JIMMY RANTS. Be sure to bookmark JimmyRants.com and dig through all of the content there during Jimmy’s time away.

Mais de 4,5 mil pacientes, em 492 centros espalhados por 33 países e apenas uma pessoa liderando este esforço de pesquisa. Neste podcast gravado durante o encontro anual do American College of Cardiology (ACC), o Dr. Renato Lopes, Ph.D., brasileiro e pesquisador do Duke Clinical Research Institute (DCRI), em Durham, na Carolina do Norte (EUA), fala ao Dr. Luís Fernando Correia sobre os desafios de liderar um estudo internacional multicêntrico.

Dr. Scott Murray is a research cardiologist with exceptional experience in interventional and preventative cardiology. He is a particular expert in the field of cardiac imaging, and has published many papers on the compelling findings from both his invasive and non-invasive studies. Dr. Murray is the current president of the British Association of Cardiovascular Prevention and Rehabilitation (BACPR). I met Scott at the Johnstown estate in County Meath, Ireland, where I had just addressed the National Institute of Preventive Cardiology of Ireland (NIPC) conference (before participating in an on-stage debate about saturated fat and nutritional guidelines - that was fun, as you can imagine!). Scott and I took the time out to have a quick chat while our wives walked in the extensive hotel grounds. We focused particularly on the latest 2018 American College of Cardiology (ACC) cardiovascular disease guidelines - which have recently given a coveted "2A" evidence level rating for the use of Coronary Artery Calcium scoring (CAC). We also cover several other topics around cardiac Imaging - such as CAC versus CTCA, ability to detect "soft plaque" using CAC - and of course what all the numbers mean for risk of heart attack and all-cause mortality.

The recent announcement of MedAxiom's merger with the American College of Cardiology (ACC) may spark questions. Pat White shares how the relationship has grown over the years and what can be expected now that we will be Transforming Cardiovascular Care, Together.

Recent recommendations from the American College of Cardiology (ACC) and the American Heart Association (AHA) have changed the criteria for diagnosing hypertension in adults. In January 2019, the ACOG will release Practice Bulletin #203 addressing these changes, and provide renewed guidance for management of chronic hypertension in pregnancy. This is PART 1, of a 2-Part review of PB#203.

An experienced senior executive with several years of experience in the pharmaceutical and biotechnology industry, Will has held key positions where he was instrumental in launching a variety of innovative platforms in medical affairs. He speaks frequently regarding the ever-changing role of medical affairs at most major medical affairs conferences and is currently president and CEO of the ACMA, whose primary mission is to create industry standards and goals for medical affairs professionals. Will has held key management roles across the industry within medical affairs, such as at Eisai, Retrophin, Gilead Sciences, Abbott Laboratories, Boehringer Ingelheim, and Merck. Will previously also served as vice president of medical and scientific affairs at CME LLC, a leading provider of continuing medical education to health care providers nationwide. He also has worked on the strategic management consulting side with companies such as Veeva Systems and often provides medical affairs consultancy services for Bain, McKinsey, BCG, Atheneum Partners, and Alpha Insights. He has published extensively and led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity, where he has collaborated with some of the nation's top research institutions, such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program, and the University of Pennsylvania's Center for Weight & Eating Disorders. Will was most recently invited to speak at the Center for Medical Technology Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, health care policy makers, physicians, and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among prediabetic overweight and obese individuals. In 2008, Will published a book entitled The Rise of Chemistry: Implications for Industry and Education. He has also held several academic appointments at Seton Hall University's School of Health and Medical Sciences; New Jersey City University; Kean University's College of Natural, Applied, and Health Sciences; and Touro Colleges of Osteopathic Medicine, Pharmacy, and Physical Therapy teaching a variety of courses, including clinical therapeutics, pharmacology, pathophysiology, and epidemiology. Will has served as a board member for the MSL Institute. He is a member of several organizations, including the American College of Cardiology (ACC), the American Diabetes Association (ADA), The Obesity Society (TOS), the American Association of Clinical Endocrinology (AACE), the American Society of Bariatric Physicians (ASBP), the American Heart Association (AHA), the Drug Information Association (DIA), and the American Chemical Society (ACS). 00:00 Will's background and how he became president and CEO of the ACMA. 02:30 The difference between a sales rep and a medical science liaison (MSL). 04:35 The need for better education among medical affairs and pharma workers. 09:10 Working with key thought leaders and the Consensus Statement they are currently working on. 12:00 How accreditation courses work to help MSLs provide more of a balanced view of a pharma product. 15:50 The pressure for Pharma and manufacturers to become Outcomes Companies. 16:25 How are MSLs evolving? 17:20 “Really, what is the value of the product?” 22:00 How ACMA remains unbiased in their course curriculum. 23:15 How health care providers can verify that they are getting the clearest unbiased pharma information possible from their MSLs. 25:25 EP187 with Sandra Leal and Todd Eury, EP181 with Dr. Lipi Roy. 25:40 The state of opioid addiction in America and how pharma information contributed to the problem. 30:05 EP148 and AEE2 with Jennifer Miller. 30:25 “It's time there's a third party that's vetting what we're doing.” 32:40 You can learn more at medicalaffairsspecialist.org.

Kim Williams, MD, is past president of the American College of Cardiology (ACC). Let's take a moment to appreciate how amazing that is. First of all, he grew up poor and black on the South Side of Chicago. One winter he ended up in the hospital with pneumonia; his family couldn't afford to buy him a coat. His step-dad died of an intercranial hemorrhage when Kim was five years old. Second, Dr Williams chose medical school over a promising career as a professional tennis player. Third, he's the first and thus far only president of the ACC to "come out" as a vegan. The current chairman of cardiology at Rush University Medical Center in Chicago has been vegan himself since 2003, and now recommends a vegan diet to his patients as the first line of defense against heart disease.

Guest: Alfred Bove, MD Host: Jack Lewin, MD The next year promises to be an important one in health policy, in cardiology and in many other areas of medicine, as we set our sights on significant transformations across our health care system. What improvements can you anticipate that will enrich your practice environment and enhance the care you provide to your patients? Host Dr. Jack Lewin welcomes Dr. Alfred Bove, the newly installed president of the American College of Cardiology (ACC), for a look ahead at key points of emphasis during the coming year, from more rigorous quality measurements, to patient empowerment and value of care, to the broader issue of health care reform and the ACC's role in furthering the priorities of cardiologists and care providers across the entire health care spectrum.

Guest: Alfred Bove, MD Host: Jack Lewin, MD The next year promises to be an important one in health policy, in cardiology and in many other areas of medicine, as we set our sights on significant transformations across our health care system. What improvements can you anticipate that will enrich your practice environment and enhance the care you provide to your patients? Host Dr. Jack Lewin welcomes Dr. Alfred Bove, the newly installed president of the American College of Cardiology (ACC), for a look ahead at key points of emphasis during the coming year, from more rigorous quality measurements, to patient empowerment and value of care, to the broader issue of health care reform and the ACC's role in furthering the priorities of cardiologists and care providers across the entire health care spectrum.